RANJANA VERMA: Open Payments
NPI 1144243783 · ABERDEEN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$670 in 26 payments from 12 companies in 2025. Trend: 2023 $423 · 2024 $656 · 2025 $670
Food & beverage: $670
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 3 | $142 |
| Teva Pharmaceuticals USA, Inc. | 6 | $139 |
| Janssen Pharmaceuticals, Inc | 2 | $74 |
| Supernus Pharmaceuticals, Inc. | 4 | $72 |
| E.R. Squibb & Sons, L.L.C. | 2 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Tris Pharma Inc | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
Products named: UZEDY, LYBALVI, SPRAVATO, Qelbree, COBENFY, CAPLYTA, ARISTADA, AUSTEDO XR.
Industry payments across MD — which companies pay providers there.
